Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. (ASMB) news on Stock Titan centers on the company’s progress in developing small-molecule therapeutics for serious viral diseases. Assembly Bio describes itself as a biotechnology company focused on herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections, and its news flow reflects clinical, scientific and corporate developments across these areas.
Investors following ASMB news can expect regular updates on clinical trial milestones. Recent press releases detail interim Phase 1b results for long-acting HSV helicase-primase inhibitor candidates ABI-5366 and ABI-1179 in participants with recurrent genital herpes, including reported reductions in HSV-2 shedding rates, high viral load shedding and genital lesion rates in certain dosing cohorts. News items also cover Phase 1b data for ABI-4334, a next-generation capsid assembly modulator candidate in chronic HBV infection, and Phase 1a interim data for ABI-6250, an oral HDV entry inhibitor candidate evaluated in healthy participants.
Another key theme in Assembly Bio’s news is its collaboration with Gilead Sciences. Company announcements describe Gilead’s rights to opt in to exclusive licenses for specific programs and report that Gilead has exercised its combined option to license the HSV helicase-primase inhibitor programs ABI-5366 and ABI-1179 for recurrent genital herpes. These items provide context on how the collaboration may influence development responsibilities, potential milestones and royalty structures.
Financial and corporate updates also feature prominently in ASMB news. Quarterly results outline collaboration revenue from Gilead, research and development spending on HSV, HBV and HDV programs, and general and administrative expenses. Additional releases describe equity financings, including an underwritten offering of common stock and warrants and a private placement with Gilead, along with the intended use of proceeds for general corporate purposes.
For investors and observers, the ASMB news feed offers a consolidated view of Assembly Biosciences’ clinical data disclosures, collaboration developments, financing activities and participation in scientific and investor conferences. Bookmarking this page can help track how the company’s antiviral pipeline and partnership with Gilead evolve over time.
Assembly Biosciences (Nasdaq: ASMB) is set to host a research webcast on August 31, 2022, from 1:30-2:30 PM PT, featuring two innovative small molecule programs targeting viral diseases. Notable speakers include CEO John McHutchison and Nobel laureate Sir Michael Houghton. The first program focuses on a unique antiviral for herpes simplex virus type 2, while the second advances a pan-herpes antiviral for serious viral infections post-transplant. The webcast will be accessible live and via replay on their website.
Assembly Biosciences (ASMB) reported its Q2 2022 financial results, highlighting a cash position of $128.6 million, funding operations until mid-2024. The company initiated a Phase 1b trial for next-generation core inhibitor ABI-H3733 and announced the discontinuation of vebicorvir's development. R&D expenses increased to $17.8 million, while the net loss was $24.5 million, or $0.51 per share. Additionally, a new small molecule interferon-α receptor agonist research program was launched, aiming for improved tolerability in HBV treatments.
Assembly Bio announces the discontinuation of clinical development for vebicorvir (VBR), its first-generation core inhibitor, based on ineffective interim efficacy data from ongoing trials. The focus will shift to next-generation core inhibitors ABI-H3733 and ABI-4334, which have shown significantly higher potency in preclinical studies. The company will undergo organizational restructuring, reducing its workforce by approximately 30%, thus extending its cash runway into the first half of 2024. Initial data from the ABI-H3733 trial is expected in H2 2022.
Assembly Biosciences (Nasdaq: ASMB) reported promising advancements in its investigational HBV core inhibitor programs ABI-H3733, ABI-4334, and vebicorvir (VBR) during the International Liver Congress 2022.
Key data highlights include:
- ABI-H3733 shows improved pharmacokinetics in a new tablet formulation.
- ABI-4334 demonstrates significant potency against HBV cccDNA formation.
- VBR, under Phase 2 studies, exhibits enhanced antiviral effects when combined with entecavir.
Assembly aims to deliver innovative therapies for the 296 million people affected by HBV worldwide.
Assembly Biosciences (ASMB) has announced a new research program focusing on a novel oral interferon-α receptor agonist, aimed at enhancing treatment for hepatitis B. This program will leverage the antiviral mechanisms of interferon-α while minimizing systemic exposure, potentially improving patient tolerability. A live webcast is scheduled for July 26, 2022, featuring key speakers including Professor Edward J. Gane and CEO John McHutchison. The company remains committed to developing curative therapies for the 296 million individuals affected by HBV globally.
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology firm, announced the acceptance of six abstracts for presentation at the International Liver Congress™ 2022 held from June 22-26. The data covers investigational core inhibitors including vebicorvir and two new candidates, ABI-H3733 and ABI-4334. CEO John McHutchison emphasized the significance of the presentations, which support the company's goal of developing finite therapies for hepatitis B virus (HBV). The posters will be accessible online for conference registrants, showcasing new insights into their drug candidates.
Assembly Biosciences, Inc. (Nasdaq: ASMB) has initiated a Phase 1b trial for its next-generation core inhibitor, ABI-H3733, targeting chronic hepatitis B virus (cHBV) infection. This trial follows a successful Phase 1a study that showed a favorable safety profile and assesses a new tablet formulation designed for once-daily dosing. Approximately 50 treatment-naïve patients will participate in a 28-day, randomized, double-blind study to evaluate the drug's safety and antiviral activity, with results supporting future Phase 2 trial dose selection.
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced a grant of stock options for 16,000 shares to a new employee at an exercise price of $1.87 per share. The options will vest over four years and were given as a material inducement for employment. This grant aligns with the company’s 2017 Inducement Award Plan and adheres to Nasdaq Listing Rule 5635(c)(4). Assembly Bio specializes in innovative therapeutics for hepatitis B virus (HBV), aiming to provide curative treatments for the 296 million people affected globally.
Assembly Biosciences (ASMB) reported its financial results for Q1 2022, highlighting a cash position of $146.5 million, down from $174.6 million at year-end 2021, expected to fund operations into Q4 2023. The company introduced a new small molecule entry inhibitor targeting HBV and HDV, expanding its pipeline. Research and development expenses decreased to $17.2 million from $18.6 million year-over-year, while general and administrative costs also fell to $6.0 million. Net loss narrowed to $23.1 million ($0.48 per share) from $27.2 million ($0.69 per share) in Q1 2021.
Assembly Biosciences (ASMB), a clinical-stage biotech company, announced the granting of stock options to a new employee for 19,000 shares at an exercise price of $2.06, the closing price on April 1, 2022. The stock options will vest over four years, with the first quarter vesting after one year. This grant is part of Assembly Bio's 2017 Inducement Award Plan and was approved by the independent Compensation Committee. Assembly Bio focuses on developing therapies for hepatitis B virus and aims to provide curative treatments for the 296 million affected individuals worldwide.